These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34479963)

  • 1. Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.
    Calvo-Vidal MN; Zamponi N; Krumsiek J; Stockslager MA; Revuelta MV; Phillip JM; Marullo R; Tikhonova E; Kotlov N; Patel J; Yang SN; Yang L; Taldone T; Thieblemont C; Leonard JP; Martin P; Inghirami G; Chiosis G; Manalis SR; Cerchietti L
    Cancer Res; 2021 Oct; 81(20):5202-5216. PubMed ID: 34479963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
    Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
    Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
    Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
    Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
    Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
    Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
    Ren Y; Bi C; Zhao X; Lwin T; Wang C; Yuan J; Silva AS; Shah BD; Fang B; Li T; Koomen JM; Jiang H; Chavez JC; Pham LV; Sudalagunta PR; Wan L; Wang X; Dalton WS; Moscinski LC; Shain KH; Vose J; Cleveland JL; Sotomayor EM; Fu K; Tao J
    J Clin Invest; 2018 Dec; 128(12):5517-5530. PubMed ID: 30260324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
    Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma.
    Xiong J; Wang L; Fei XC; Jiang XF; Zheng Z; Zhao Y; Wang CF; Li B; Chen SJ; Janin A; Gale RP; Zhao WL
    Blood Cancer J; 2017 Jul; 7(7):e0. PubMed ID: 28686226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
    Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
    Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic acidic nuclear phosphoproteins ANP32C/D are novel clients of heat shock protein 90.
    Yuzefovych Y; Blasczyk R; Huyton T
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2338-48. PubMed ID: 26112988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.
    Valera A; Colomo L; Martínez A; de Jong D; Balagué O; Matheu G; Martínez M; Taddesse-Heath L; Jaffe ES; Bacchi CE; Campo E
    Mod Pathol; 2013 Oct; 26(10):1329-37. PubMed ID: 23599149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies.
    Ortega M; Bhatnagar H; Lin AP; Wang L; Aster JC; Sill H; Aguiar RC
    Leukemia; 2015 Apr; 29(4):968-76. PubMed ID: 25311243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of Notch1 by the Hsp90 Chaperone Is Crucial for T-Cell Leukemogenesis.
    Wang Z; Hu Y; Xiao D; Wang J; Liu C; Xu Y; Shi X; Jiang P; Huang L; Li P; Liu H; Qing G
    Clin Cancer Res; 2017 Jul; 23(14):3834-3846. PubMed ID: 28143869
    [No Abstract]   [Full Text] [Related]  

  • 17. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.
    Abramson JS; Chen W; Juszczynski P; Takahashi H; Neuberg D; Kutok JL; Takeyama K; Shipp MA
    Br J Haematol; 2009 Feb; 144(3):358-66. PubMed ID: 19036086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
    Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS
    Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
    Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
    Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.